Arrowhead Pharmaceuticals, Inc. financial data

Symbol
ARWR on Nasdaq
Location
177 E Colorado Blvd, Suite 700, Pasadena, CA
Fiscal year end
September 30
Latest financial report
10-Q - Q2 2025 - Aug 7, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 547 % +10%
Return On Equity -40.9 % +75.4%
Return On Assets -11.6 % +82.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 138M shares +11.2%
Common Stock, Shares, Outstanding 138M shares +11.2%
Entity Public Float 3B USD +30.4%
Common Stock, Value, Issued 230K USD +5.99%
Weighted Average Number of Shares Outstanding, Basic 139M shares +11.9%
Weighted Average Number of Shares Outstanding, Diluted 139M shares +11.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 573M USD +2816%
General and Administrative Expense 113M USD +16.2%
Operating Income (Loss) -108M USD +80.3%
Nonoperating Income (Expense) -49.4M USD -3320%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -157M USD +71.3%
Income Tax Expense (Benefit) -437K USD
Net Income (Loss) Attributable to Parent -148M USD +72.4%
Earnings Per Share, Basic -1 USD/shares +73.7%
Earnings Per Share, Diluted -1 USD/shares +73%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 69.4M USD -34.1%
Accounts Receivable, after Allowance for Credit Loss, Current 9.7M USD
Other Assets, Current 13.2M USD +215%
Assets, Current 947M USD +110%
Property, Plant and Equipment, Net 381M USD +1.37%
Operating Lease, Right-of-Use Asset 44M USD -0.76%
Other Assets, Noncurrent 1.35M USD -69.7%
Assets 1.38B USD +56.2%
Accounts Payable, Current 33.1M USD +24.5%
Employee-related Liabilities, Current 19.3M USD +22.2%
Accrued Liabilities, Current 64.8M USD +35.3%
Contract with Customer, Liability, Current 23M USD
Liabilities, Current 195M USD +101%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 106M USD -5.67%
Other Liabilities, Noncurrent 669K USD
Accumulated Other Comprehensive Income (Loss), Net of Tax 5.36M USD
Retained Earnings (Accumulated Deficit) -1.6B USD -10.2%
Stockholders' Equity Attributable to Parent 522M USD +58%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 520M USD +53.3%
Liabilities and Equity 1.38B USD +56.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -146M USD -24.1%
Net Cash Provided by (Used in) Financing Activities 20.6M USD +7628%
Net Cash Provided by (Used in) Investing Activities 76.9M USD +18.6%
Common Stock, Shares Authorized 290M shares 0%
Common Stock, Shares, Issued 138M shares +11.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 130M USD +87%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD
Deferred Tax Assets, Valuation Allowance 449M USD +57.7%
Deferred Tax Assets, Gross 473M USD +55.4%
Operating Lease, Liability 113M USD -4.57%
Payments to Acquire Property, Plant, and Equipment 7.52M USD -89.1%
Lessee, Operating Lease, Liability, to be Paid 177M USD -7.62%
Property, Plant and Equipment, Gross 455M USD +5.92%
Operating Lease, Liability, Current 7.01M USD +15.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 15M USD -4.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 15.8M USD +2.89%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 64.3M USD -12.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 13.6M USD -8.41%
Deferred Tax Assets, Operating Loss Carryforwards 103M USD +69.8%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 16.6M USD +14.3%
Lessee, Operating Lease, Liability, to be Paid, Year Four 13.9M USD +2.92%
Operating Lease, Payments 15.3M USD +85.7%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 1.7M USD 0%
Depreciation, Depletion and Amortization 20.8M USD +33.3%
Share-based Payment Arrangement, Expense 59.4M USD -11.6%
Interest Expense 23M USD +43.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%